Scientists discover how common treatment-related cancer develops

May 31, 2012
Scientists discover how common treatment-related cancer develops

(Medical Xpress) -- Scientists in a team at Newcastle University have identified a mechanism by which treatment-related leukaemia develops, raising hopes that this side effect of toxic chemotherapy could be prevented.

Acute (AML) is a that can arise as a consequence of treatment for other cancers. AML is diagnosed in 2,200 adults each year and it is thought that up to 10% of these cases are treatment-related.

Leukaemia is often triggered by DNA mutations within when part of one chromosome exchanges with part of another in a process called translocation. For these chromosome rearrangements to occur, their constituent DNA must be broken and then repaired incorrectly. These mutated cells then divide uncontrollably in the blood, crowding out healthy blood cells.

Up to a third of treatment-related cases of AML can be attributed to chromosome rearrangements caused by the interaction between anti-cancer drugs and an enzyme called ‘TOP2B’. This enzyme is critical in managing DNA movement within cells and many cancers including lymphoma, testicular, lung and prostate cancers are sensitive to drugs that block its activity.

In work funded by the charity Leukaemia & Lymphoma Research and published online in the journal Proceedings of the National Academy of Sciences, the Newcastle scientists showed that while drugs designed to inhibit TOP2 can be highly effective in preventing the rapid division of cancer cells, in some cases these drugs also cause key regions of important to be held close together in a manner that increases the likelihood that the leukaemia inducing translocations occur.

Professor Caroline Austin, who led the team at the Institute for Cell and Molecular Biosciences at Newcastle University, said: “We are working to understand more about how these DNA breaks and rearrangements are made. The hope is that we will now be able to find ways of altering drug treatments to block this process, preventing secondary cancers from developing.”

Professor Chris Bunce, Research Director at Leukaemia & Lymphoma Research, said: “Although thankfully relatively rare, diagnosis with a second cancer due to treatment is a devastating blow for patients. It is vital that we reform and improve standard chemotherapy drugs to not just make them more effective but also reduce side-effects. This study represents a huge breakthrough. It is the first time that scientists have looked into what is going on in the cell nucleus and explained exactly what happens when treatment-related occur.”

Explore further: Scientists find new drug target for hard-to-treat leukaemia

Related Stories

Scientists find new drug target for hard-to-treat leukaemia

March 30, 2012

(Medical Xpress) -- Cancer Research UK scientists have discovered a promising new approach to treat a type of myeloid leukaemia – a cancer with limited treatment options and relatively poor survival, according to research ...

Researchers’ blood cancer breakthrough

August 10, 2011

Researchers at the University of Southampton have discovered clues to why many patients do not respond to a standard drug for the blood cancer lymphoma, raising hopes that more effective treatments can be designed.

Recommended for you

Opinion: How dangerous is burnt toast?

January 23, 2017

A new campaign is warning people that burning some food, such as toast, is a potential cancer risk. Here, the evidence for this claim is explored by David Spiegelhalter, Professor of the Public Understanding of Risk at the ...

Pancreatic tumors rely on signals from surrounding cells

January 19, 2017

Just as an invasive weed might need nutrient-rich soil and water to grow, many cancers rely on the right surroundings in the body to thrive. A tumor's microenvironment—the nearby tissues, immune cells, blood vessels and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.